IMPROVED BUFFER GEL FOR IONTOPHORESIS ELECTRODES

• US 20050197618A1
• Filed: 03/03/2004
• Published: 09/08/2005
• Est. Priority Date: 03/03/2004
• Status: Abandoned Application

• Current Assignee: Encore Medical Asset Corporation (Enovis Corp.)
• Original Assignee: Iomed, Inc. (Enovis Corp.)
• Inventors: Szlek, Malgorzata, Plummer, Thomas, Beck, Jon E.
• Application Number:
  US10/708,432
• Publication Number:
  US 20050197618A1
• Time in Patent Office: Days
• US Class Current: 604/20
• CPC Class Codes: A61N 1/30 Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis

Abstract

An iontophoretic delivery device utilizing a polymeric gel matrix to ameliorate pH deviation within the device wherein the pH of the polymeric gel matrix is buffered at select pH ranges in order to reduce skin irritation. The polymeric gel matrix is housed within the iontophoretic delivery device as a buffering agent wherein the matrix provides a suitable physiological pH level above 4.0 and particularly the pH level deviates between approximately 4.1 to approximately 4.9, and preferably at the pH 4.5 for an effective operation of the iontophoretic delivery of a medicament to treat affected areas of a living subject'"'"'s body.

Claims

1. An iontophoretic device for delivering a medicament to treat an affected area of a living subject'"'"'s body wherein said iontophoretic device is configured for transdermal application, wherein the device comprises:

a buffering agent associated with a polymeric gel matrix;

wherein

the buffering agent further comprises polymers having pendant carboxylic acid moieties which can maintain pH of the gel matrix from approximately 4.1 to approximately 4.9, and, preferably pH 4.5, for iontophoresis applications;

a viscosity enhancer associated with the polymeric gel matrix to temporarily store the medicament in the matrix;

a rehydrating agent associated with the polymeric gel matrix to facilitate homogeneous hydration in the matrix;

a medicament associated with the polymeric gel matrix; and

an active electrode assembly associated with the polymeric gel matrix configured for iontophoretically delivering the medicament to the affected area of the living subject'"'"'s body.

2. The iontophoretic device according to claim 1, wherein the medicament associated with the polymeric gel matrix may be selected from the group consisting of:

Dexamethasone; and

Lidocaine.

3. The iontophoretic device according to claim 1, wherein the medicament may be selected from the group consisting of the following chemical structures:

4. The iontophoretic delivery device according to claim 1, further comprising:

a counter electrode assembly, wherein the counter electrode assembly is configured for completing an electrical circuit between the active electrode assembly and an energy source; and

an energy source for generating an electrical potential difference.

5. The iontophoretic device according to claim 1, wherein the buffering agent is any neutralized acrylate polymer having the following structure:

6. The buffering agent according to claim 5, wherein the neutralized acrylate polymer is neutralized with any one of soluble amino acids having the following chemical structure:

7. The iontophoretic device according to claim 1, wherein the viscosity enhancer capable of temporarily storing the medicament is hydroxy ethyl cellulose.

8. The iontophoretic device according to claim 1, wherein the rehydrating agent capable of facilitating hydration of the matrix is a Tween-A20.

9. The iontophoretic device according to claim 1, wherein the active electrode assembly includes an open-faced or high current density electrode.

10. A method for treating an affected area of a living subject'"'"'s body, wherein the method comprises the steps of:

associating a medicament with a matrix in an iontophoretic delivery device;

providing an effective amount of pH buffering agents to the matrix;

attaining high buffer capacity by providing a viscosity enhancer to the matrix;

adding a rehydration agent to the matrix to facilitate homogeneous hydration within the matrix;

positioning at least a portion of the iontophoretic device on the affected area of a living subject; and

iontophoretically delivering the medicament to the affected area of the living subject to minimize skin inflammation.

11. The method according to claim 10, wherein the matrix configured for iontophoretically delivering the medicament to the affected area of the living subject'"'"'s body further comprises the steps of:

means for maintaining a pH above 4.0; and

means for deviating a pH in the ranges from approximately 4.1 to approximately 4.9, and, preferably pH 4.5, for transdermal iontophoretic delivery of the medicament to the affected area of the limiting subject'"'"'s body.

12. The method according to claim 10, wherein the step of administering a medicament may be selected from the group consisting of the following chemical structures:

13. The method according to claim 10, wherein the step of administering a medicament with the living subject includes the step of providing pH buffering agents and any one of amino acids wherein both work in concert to maintain pH above pH 4.0 and assure minimal deviations from a pH of about pH 4.5.

14. The method according to claim 10, wherein the step of administering a medicament with the living subject includes the step of providing any one of viscosity enhancers to store the medicament in place of the matrix.

15. The method according to claim 10, wherein the step of administering a medicament with the living subject includes the step of providing rehydrating agents to facilitate hydration of the matrix, wherein the rehydrating agent further comprises Waterlock A220.